BIPLR IM EN PAC LEADS (430-07,432-03,436-02 & 07, 438-05 & 07)

K962174 · Intermedics, Inc. · DTB · Aug 21, 1996 · Cardiovascular

Device Facts

• Record ID: K962174
• Device Name: BIPLR IM EN PAC LEADS (430-07,432-03,436-02 & 07, 438-05 & 07)
• Applicant: Intermedics, Inc.
• Product Code: DTB · Cardiovascular
• Decision Date: Aug 21, 1996
• Decision: ST
• Submission Type: Traditional
• Regulation: 21 CFR 870.3680
• Device Class: Class 3
• Attributes: Therapeutic

Intended Use

Pacing leads are intended for use with implantable cardiac pulse generators for long-term pacing of the heart. The indications for ventricular pacing include, but are not limited to: Sick sinus syndrome, sinus bradycardia, complete heart block, and certain conditions of asymptomatic second-degree block. In the presence of normal A-V conduction the indications for atrial pacing include, but are not limited to: Sinus arrest, sick sinus syndrome, sinus bradycardia and conditions requiring increased cardiac efficiency, enhanced cardiac output or the overdrive of certain cardiac arrhythmias. In the absence of normal A-V conduction, an atrial lead may be used with a ventricular lead in a dual-chamber pacing system to restore A-V synchrony. Active fixation leads are specifically indicated for use in cases where passive-fixation leads provide unsatisfactory positional stability in either the atrium or the ventricle, or in cases where the atrial appendage has been sacrificed due to open-heart surgery or is abnormal because of congenital or acquired heart disease.

Device Story

Bipolar implantable endocardial pacing leads (Models 430-07, 432-03, 436-02, 436-07, 438-05, 438-07) designed for long-term cardiac pacing. Leads connect to implantable pulse generators to deliver electrical stimulation to the myocardium. Features include iridium-oxide coated titanium, carbon-coated titanium, or platinum-iridium electrodes; trifilar nickel-cobalt conductor coils; and polyurethane or silicone rubber sheaths. Fixation mechanisms include passive trailing tines or active helical corkscrews. Model 438-07 includes a soluble PEG capsule for active fixation protection during venous transit. Device used by physicians in clinical settings for cardiac rhythm management. Benefits include restoration of cardiac output and rhythm regulation. Modification involves transition to CFC-free manufacturing process using IPA/heptane blend.

Clinical Evidence

No new clinical data provided. Substantial equivalence is supported by biocompatibility testing (hemolysis, cytotoxicity, USP Class V, Ames mutagenicity, sensitization) and qualification testing on representative models. Materials processed with IPA/heptane blend demonstrated biocompatibility equivalent to previous manufacturing methods.

Technological Characteristics

Bipolar endocardial pacing leads. Electrodes: IROX (iridium-oxide coated titanium), Biolite (carbon-coated titanium), or Pt/Ir alloy. Conductor: Trifilar nickel-cobalt alloy. Insulation: Polyurethane or silicone rubber. Fixation: Passive (silicone tines) or Active (Ni-Co helical screw). Connector: VS.1 standard. Sterilization: Ethylene oxide (EO) per AAMI 1988 guidelines.

Indications for Use

Indicated for patients requiring long-term cardiac pacing due to sick sinus syndrome, sinus bradycardia, heart block, or sinus arrest. Atrial leads indicated for dual-chamber systems to restore A-V synchrony. Active fixation indicated for cases with unsatisfactory passive-fixation stability or abnormal/sacrificed atrial appendages. Contraindicated in tricuspid atresia, Ebstein's malformation, atrial/ventricular transposition, mechanical tricuspid valves, atrial paralysis, atrial atrophy, or atrial fibrillation.

Regulatory Classification

Identification

Temporary pacemaker electrode: A device consisting of flexible insulated electrical conductors with one end connected to an external pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator. Permanent pacemaker electrode: A device consisting of flexible insulated electrical conductors with one end connected to an implantable pacemaker pulse generator and the other end applied to the heart. The device is used to transmit a pacing electrical stimulus from the pulse generator to the heart and/or to transmit the electrical signal of the heart to the pulse generator.

Predicate Devices

• Intermedics Model 430-07 (K890412, K902672, K954610, K954719)
• Intermedics Model 432-03 (K890411, K912235, K954610, K954719)
• Intermedics Model 436-02 (K883602, K954719)
• Intermedics Model 436-07 (K955122)
• Intermedics Model 438-05 (K922972, K954719)
• Intermedics Model 438-07 (K955550)

Submission Summary (Full Text)

{0}

K962174

AUG 21 1996

# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.

The assigned 510(k) number is:

(To be completed by FDA)

# TABLE OF CONTENTS

A. GENERAL INFORMATION 2
B. DESCRIPTION OF THE DISEASES AND CONDITIONS FOR WHICH THE CFC-FREE PACING LEADS ARE INDICATED 3
C. DEVICE DESCRIPTION 4
1. Labeling 6
2. Design and Materials 7
3. Performance 9
D ALTERNATIVES 9
E. POTENTIAL ADVERSE EFFECTS 10
F. SUMMARY OF STUDIES 10
1. Biocompatibility Studies 10
2. Qualification Testing 11
G. CLINICAL SUMMARY 12
H. MANUFACTURING/STERILIZATION 12
I. CONCLUSION 13

0067

{1}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

A. GENERAL INFORMATION

Device Classification Name:
Electrode, Pacemaker, Permanent and Temporary

Device Trade Name:
- Intermedics Model 430-07 Bipolar Implantable Endocardial Pacing Lead
- Intermedics Model 432-03 Bipolar Implantable Endocardial Pacing Lead
- Intermedics Model 436-02 Bipolar Implantable Endocardial Pacing Lead
- Intermedics Model 436-07 Bipolar Implantable Endocardial Pacing Lead
- Intermedics Cardifix EZ Model 438-05 Bipolar Implantable Endocardial Pacing Lead
- Intermedics Cardifix EZ Model 438-07 Bipolar Implantable Endocardial Pacing Lead

Applicant's Name and Address:
Intermedics Inc. (Establishment Registration Number: 1640319)
4000 Technology Drive
Angleton, TX 77515

Primary Company Representative:
Lori Kleinschrodt Holder, RAC
Regulatory Affairs Specialist
[phone] FAX: [phone]

Alternate Company Representative:
Kathleen M. Chester, RAC
Senior Regulatory Affairs Specialist
[phone] FAX: [phone]

Date of Notification:
June 4, 1996

0008

{2}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

B. DESCRIPTION OF THE DISEASES AND CONDITIONS FOR WHICH THE CFC-FREE MANUFACTURED PACING LEADS ARE INDICATED

The indications for use of Intermedics Models 430-07, 432-03, 436-02, 436-07, 438-05, and 438-07 endocardial pacing leads, manufactured using a Chlorofluorocarbon (CFC) Free process, are identical to those for the commercially available leads with the same model numbers manufactured using Freon-TMS.

Pacing leads are intended for use with implantable cardiac pulse generators for long-term pacing of the heart. The indications for ventricular pacing include, but are not limited to: Sick sinus syndrome, sinus bradycardia, complete heart block, and certain conditions of asymptomatic second-degree block.

In the presence of normal A-V conduction the indications for atrial pacing include, but are not limited to: Sinus arrest, sick sinus syndrome, sinus bradycardia and conditions requiring increased cardiac efficiency, enhanced cardiac output or the overdrive of certain cardiac arrhythmias.

In the absence of normal A-V conduction, an atrial lead may be used with a ventricular lead in a dual-chamber pacing system to restore A-V synchrony.

Active fixation leads are specifically indicated for use in cases where passive-fixation leads provide unsatisfactory positional stability in either the atrium or the ventricle, or in cases where the atrial appendage has been sacrificed due to open-heart surgery or is abnormal because of congenital or acquired heart disease.

Contraindications

The use of endocardial leads may be contraindicated in the presence of tricuspid atresia, Ebstein's malformation, and various forms of atrial or ventricular transposition, and in patients with mechanical tricuspid heart valves. The use of endocardial leads for atrial indications may be contraindicated in the presence of atrial paralysis, atrial atrophy, or a surgically modified or excised atrial appendage.

0069

{3}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

Atrial pacing is contraindicated in the presence of atrial fibrillation and, except when used in a dual chamber system, in the presence of certain A-V conduction defects.

## C. DEVICE DESCRIPTION

The Intermedics Models 430-07, 432-03, 436-02, 436-07, 438-05, and 438-07 endocardial pacing leads are designed for use with implantable cardiac generators for long term cardiac pacing. Table 1 summarizes the accessories packaged with each lead model.

0010

{4}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

TABLE 1. Accessories packaged with each lead model.

| Accessory | Lead Model | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | 430-07 | 432-03 | 436-02 | 436-07 | 438-05 | 438-07 |
| 365-11
Limber Stylet | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ |
| 365-12
Firm Stylet | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ |
| 365-57
Limber Large "J" Stylet | ☐ | ☐ | ☐ | ☐ | ☑ | ☐ |
| 365-58
Firm Large "J" Stylet | ☐ | ☐ | ☐ | ☐ | ☑ | ☐ |
| 365-81
Tapered Limber Stylet | ☐ | ☐ | ☐ | ☑ | ☐ | ☐ |
| 365-82
Tapered Firm Stylet | ☐ | ☐ | ☐ | ☑ | ☐ | ☐ |
| 365-87
Limber Tight "J" Stylet | ☐ | ☐ | ☐ | ☐ | ☑ | ☐ |
| 365-89
Limber "J" Stylet | ☐ | ☐ | ☐ | ☐ | ☐ | ☑ |
| 365-90
Firm "J" Stylet | ☐ | ☐ | ☐ | ☐ | ☐ | ☑ |
| 366-14
Lead Cover | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| 366-29
Step up adapter VS.1 to 5mm | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| 366-30
Step up adapter VS.1 to 6mm | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| 367-01
Vein Lifter | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ |
| Stylet Funnel
(no model no.) | ☑ | ☑ | ☐ | ☐ | ☐ | ☐ |

5

0011

{5}

510(k) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(k) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

With the exception of the solution used during the manufacturing process, the listed pacing leads manufactured with the CFC-free process are identically configured to the commercially available Intermedics pacing leads with the same model numbers. Table 2 lists the 510(k) numbers and approval dates for each lead model.

Table 2. 510(k) Numbers and approval dates for each lead model.

| Lead Model | 510(k) Number | Approval Date |
| --- | --- | --- |
| 430-07 | K890412 | 3/28/89 |
| | K902672 | 3/1/91 |
| | K954610 | Submitted 10/03/95 |
| | K954719 | 2/27/96 |
| 432-03 | K890411 | 03/28/89 |
| | K912235 | 09/26/91 |
| | K954610 | Submitted 10/03/95 |
| | K954719 | 2/27/96 |
| 436-02 | K883602 | 09/06/88 |
| | K954719 | 02/27/96 |
| 436-07 | K955122 | Submitted 11/07/95 |
| 438-05 | K922972 | 01/22/93 |
| | K954719 | 02/27/96 |
| 438-07 | K955550 | Submitted 12/04/95 |

1. Labeling

There are no changes to the product labeling as a result of the modification to the manufacturing process.

6

0012

{6}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS
SECTION 2 - 510(K) SUMMARY SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

## 2. Design and Materials

The general characteristics of the pacing leads are summarized below. Table 3 summarizes the characteristics of each lead by model number.

### a. Electrodes

The cathode tip electrode transfers the electrical charge from the pulse generator to the desired cardiac surface (endocardium, epicardium, or myocardium) via the pacing lead. This electrical charge stimulates the myocardium, causing cardiac depolarization. The electrodes are either made of iridium-oxide coated titanium (IROX™) (models 430-07, 432-03, 436-07, 438-07), carbon-coated (Biolite¹) titanium (model 436-02) or a platinum-iridium alloy (model 438-05).

### b. Lead Body

The conductor coils, constructed of three nickel-cobalt alloy wires wound uniaxially (trifilar), transmit electrical activity to and from the heart. Electrical isolation between the connectors and the body environment is provided by an sheath surrounding the conductor coil: which also contributes to the structural strength of the leads. The sheath may be made of polyurethane (models 430-07, 432-03, 438-05, 438-07) or silicone rubber (models 436-02, 436-07).

### c. Tip Fixation

The passive fixation mechanism of the lead tip of the models 430-07, 432-03, 436-02, and 436-07 lodges among the trabeculae in order to prevent dislodgement or movement of the tip electrode from the endocardium. The tip fixation mechanism, made of silicone rubber, is a trailing tines design with radial projections 45° to the axis of the lead body.

¹Biolite is a trademark of Carbomedics, Inc., Austin, TX.

7
0013

{7}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

TABLE 3. Characteristics of Intermedics Pacing Leads by Model Number.

| Model No. | Chamber^{1} | Polarity | Length^{2} (cm) | Electrode Material | Lead Body Material | Fixation | Connector |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 430-07 | Ventricular | Bipolar | 58 | IROX | Polyurethane | Passive/Tine | VS. 1 |
| 432-03 | Atrial | Bipolar | 52 | IROX | Polyurethane | Passive/Tine | VS. 1 |
| 436-02 | Ventricular | Bipolar | 60 | Biopore | Silicone | Passive/Tine | VS. 1 |
| 436-07 | Ventricular | Bipolar | 58 | IROX | Silicone | Passive/Tine | VS. 1 |
| 438-05 | A/V | Bipolar | 60 | Pt/IR | Polyurethane | Active/Screw | VS. 1 |
| 438-07 | A/V | Bipolar | 58 | IROX | Polyurethane | Active/Screw | VS. 1 |

1A/V - Atrial and Ventricular

2Nominal Lengths. Other lengths available upon request.

8

{8}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

The active fixation mechanism of the lead tips of the models 438-05 and 438-07 consists of a nickel-cobalt helical corkscrew which is fixed in the endocardium in order to prevent dislodgement or movement of the tip. The model 438-07 pacing lead has a unique feature which provides a protective soluble Polyethylene Glycol (PEG) capsule over the fixation mechanism while the lead is passed through the venous system. Within 2 to 4 minutes, the PEG dissolves allowing fixation of the lead into the cardiac tissue.

d. Connector Assembly

For all Intermedics pacing lead models, the connector pin (cathode), made of 316 stainless steel, provides the electrical and mechanical connection between the pulse generator and pacing lead. The connector sleeve and seals are made of silicone rubber and provide an insulating seal between the lead and the header of the pulse generator. The connector dimensions are designed to meet the requirements of the VS. 1 standard.

3. Performance

The Intermedics pacing leads are intended for use with implantable pulse generators. Based upon the results of qualification testing, the performance of the leads manufactured with the CFC-free manufacturing process is expected to be equivalent to the performance of the commercially available leads manufactured using Freon-TMS.

D. ALTERNATIVES

The alternatives to the use of pacing leads are similar to those described for pulse generators. Surgery or drug therapy have been stated as alternatives to cardiac pacing in certain instances. However, when a cardiac pacing system is employed, the side effects of drugs and/or the risks of surgery make these alternatives less desirable.

Other commercially available pacing leads provide another alternative to the use of Intermedics pacing leads manufactured using the CFC-free process.

9

0015

{9}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS
SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

## E. POTENTIAL ADVERSE EFFECTS

The potential adverse effects associated with the use of pacing leads may include intermittent or continuous loss of pacing or sensing produced by factors such as displacement of the electrode, unsatisfactory electrode position, breakage of the conductor or its insulation, an increase in thresholds, or poor electrical connection to the pulse generator. As with the introduction of any foreign object into the body, infection can result from the use of pacing leads and accessories. These complications can occur during implantation, explantation, or at any time postoperatively and may require noninvasive or invasive management techniques.

When subclavian venipuncture is used for endocardial lead introduction, "extremely medial" insertion of a lead and/or "anatomic abnormalities" may contribute to conductor fracture². Perforation of the ventricular wall may cause phrenic nerve stimulation or diaphragmatic muscle stimulation. Cardiac tamponade has been reported from instances of lead perforation.

When removing an implanted endocardial lead, if the connector is cut off, the lead's insulation tubing, under sufficient traction, may separate from the lead conductor and slide off, leaving an exposed conductor coil in the heart and vein.

When using an epicardial or myocardial lead, conditions may occur that are associated with risks inherent in open chest surgery, such as pulmonary difficulties and, rarely, cardiac tamponade.

## F. SUMMARY OF STUDIES

### 1. Biocompatibility Studies

All of the tissue/fluid contacting materials of the pacing leads have been evaluated for biocompatibility in both in vitro and in vivo test systems and subjected to the following tests:

²Stokes K, et al: A possible "new" complication of subclavian stick: Conductor fracture, PACE, 10:748, 1987 (Abstract).

10
0016

{10}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

- Hemolysis Test
- MEM Elution Cytology
- Ames Mutagenicity
- USP Class V
- Intramuscular Implantation Test
- Maximization Sensitization Test
- USP Pyrogen Test

Based upon the test data, the materials above were not found to present any toxic liability under physiological conditions. Therefore, the tissue/fluid contacting materials of this pacing system are considered biocompatible.

In order to ensure continued biocompatibility of these materials when manufactured utilizing the IPA/heptane blend, the hemolysis and cytotoxicity tests were repeated for the following materials:

- Silicone tubing cleaned with IPA/heptane,
- 80A polyurethane tubing cleaned with IPA/heptane,
- 55D polyurethane tubing cleaned with IPA/heptane.

Based upon the results of these tests, the materials continue to be biocompatible when processed with the IPA/heptane blend.

## 2. Qualification Testing

Qualification testing was performed on the model 430-07. This lead model was selected as it consists of processes representative of the changes in the manufacturing processes of the affected lead models as a result of the elimination of Freon-TMS. These processes include:

- Cleaning (degreasing) of silicone, polyurethane, and metal parts
- Swelling of silicone tubing and parts
- Softening and lubricating of polyurethane tubing
- Mechanical assembly of components

0017

{11}

510(K) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS

SECTION 2 - 510(K) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

# G. CLINICAL SUMMARY

The clinical experience of the commercially available Intermedics pacing leads has resulted in an extremely low incidence of clinical complications, demonstrating its effective performance in human implantation. Because of the favorable biocompatibility and qualification test results, it is expected that the pacing leads manufactured with the CFC-free process will perform with comparable efficacy.

# H. MANUFACTURING/STERILIZATION

Intermedics utilizes environmental controls in the manufacturing facilities which are designed, maintained and closely monitored to achieve an efficacious environment for manufacturing all products. The manufacturing environment is routinely monitored for particle counts, humidity, temperature, and static electricity controls. Additionally, bioburden testing is performed on all products.

Vendors of purchased material must be "approved" based upon a quality survey in which Intermedics' field engineers determine whether the vendor has the capability of consistently supplying material that will meet Intermedics' standards. Each quantity of purchased material is assigned a lot number and acceptance or rejection is determined based upon an inspection (conducted on a statistical sampling basis) performed to Intermedics' Engineering specifications.

The finished pacing lead and accessories are packaged in the formed pockets of an inner blister tray which is closed by heat sealing a peelable cover around the periphery. This inner blister is then placed into an outer blister which is closed by heat sealing a second peelable cover to it. Cover material is microbial penetration resistant, water resistant, and puncture resistant as suitable for this application.

Intermedics sterilization procedures for pacing leads and accessories utilize ethylene oxide (EO) sterilizers set for specific parameters derived using methods described in the 1988 AAMI guideline, Guideline for Industrial Ethylene Oxide Sterilization of Medical Devices.

003

{12}

510(k) NOTIFICATION - CFC-FREE MANUFACTURING PROCESS
SECTION 2 - 510(k) SUMMARY, SUMMARY OF ADVERSE SAFETY AND EFFECTIVENESS DATA, AND CERTIFICATION

Upon release from sterilization, pacing lead and accessories are packaged into a carton and the boxed product is inspected prior to being routed to the Finished Goods Inventory area.

## I. CONCLUSION

The information presented in this submission for the Intermedics Models 430-07, 432-03, 436-02, 436-07, 438-05, and 438-07 endocardial pacing leads demonstrates that the intended use of these devices does not differ from that of the commercially available predicate models.

The clinical experience of the Intermedics endocardial pacing leads has resulted in an extremely low incidence of clinical complications, demonstrating their effective performance in human implantation. Because of the similarity in design and materials, the pacing leads can be expected to perform with